Company intelligence / Profile preview
Otic Pharma
Israeloticpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Prior to its merger with Tokai Pharmaceuticals in May 2017, Otic Pharma was a clinical-stage pharmaceutical company developing novel therapies for ear, nose, and throat disorders. Its lead program was OP‑02—a nasally-administered combination product targeting the underlying cause of recurrent/chronic otitis media and Eustachian tube dysfunction. The company also developed a foam-based delivery platform intended as an improved treatment option for acute otitis externa. At the time of merger completion, OP‑02 had completed or was completing Phase I studies with plans to enter Phase II trials.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Combination drug products (nasally-administered)Foam-based drug delivery systems
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Otic Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otic Pharma.